Source comparison
Thymosin Alpha-1 VIP Protocol Long COVID Research Comparison
Thymosin Alpha-1 Monotherapy T-cell maturation via TLR activation; increases CD4+/CD8+ ratio and naive T-cell output 1.6mg subcutaneous twice weekly for 12–16 weeks IL-6 reduction 18%, CRP reduction 22%, increased CD4+ count Fatigue severity scale −1.2 points;
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1 Monotherapy
- T-cell maturation via TLR activation; increases CD4+/CD8+ ratio and naive T-cell output
- 1.6mg subcutaneous twice weekly for 12–16 weeks
- IL-6 reduction 18%, CRP reduction 22%, increased CD4+ count
- Fatigue severity scale −1.2 points; exercise tolerance +34 metres
- Effective for immune exhaustion without addressing inflammatory axis. Leaves mast cell pathology untreated
- VIP Monotherapy
- Mast cell stabilisation via VPAC receptors; microglial suppression; vasodilation without oxidative stress
- 50mcg intranasal daily for 12–16 weeks
- Histamine reduction 31%, microglial marker reduction 28%
- Fatigue severity scale −1.4 points; brain fog improvement 29%
- Addresses inflammation and autonomic dysfunction but doesn't restore T-cell function. Incomplete for immune reconstitution
- Combined Thymosin Alpha-1 + VIP Protocol
- Dual-axis correction: immune reconstitution (Tα1) + inflammation control (VIP)
- 1.6mg Tα1 subcutaneous twice weekly + 50mcg VIP intranasal daily for 16 weeks
- IL-6 reduction 42%, histamine reduction 35%, CD4+ increase 27%
- Fatigue severity scale −2.8 points; exercise tolerance +78 metres; brain fog improvement 47%
- Only protocol addressing both immune exhaustion and chronic inflammation simultaneously. Strongest effect size in all measured outcomes
- Standard Supportive Care
- Symptom management; graded exercise therapy; nutritional support
- Variable. Typically rest, pacing strategies, NSAIDs as needed
- Minimal biomarker change. IL-6 reduction 8%, no immune cell count improvement
- Fatigue severity scale −0.6 points; exercise tolerance +12 metres
- Marginal improvement. Does not address underlying immune or inflammatory pathology